What is CYP1A2 (rs762551)? And Why Does the Toxin Zoomer Test for It?

Phase I xenobiotic enzyme variant

CYP1A2 (rs762551) is a common genetic variant in the CYP1A2 gene that influences activity of a phase I liver enzyme. That enzyme helps chemically modify many environmental chemicals and some drugs, so genotypes can hint at individual differences in how the body processes toxicants. Measuring this variant adds genetic context when interpreting toxicant levels and detox capacity.

View Toxin Zoomer

CYP1A2 (rs762551)

Quality and Security

High-quality testing run in a CLIA-certified and CAP-accredited lab in Santa Clara, California.

fortified-health-HIPAA-compliance-pqgjtx4popoe2n0arp68hrz8h2as5rlhgng5b2srk8 1

About CYP1A2 (rs762551)

${ activeTab.tab_content.text }

View ${ activeTab.tab_content.btn_label }

About CYP1A2 (rs762551)

Overview and History

CYP1A2 is a member of the cytochrome P450 family of enzymes, a group of heme-containing monooxygenases involved in phase I metabolism. The rs762551 site is a single nucleotide variant in the CYP1A2 gene that has been studied in pharmacogenetics and environmental health for its association with altered enzyme inducibility and activity. Biologically, CYP1A2 helps add oxygen to or otherwise modify many small molecules—including dietary compounds, environmental chemicals, and some medications—making them easier for the body to process further. Variants like rs762551 have been noted in research on caffeine metabolism and chemical activation pathways, highlighting inter-individual differences in metabolic response.

Interpreting Highs and Lows

Predicted higher CYP1A2 activity (often described as “elevated”) may be associated with faster initial metabolism of some chemicals and drugs, which can shorten exposure time for parent compounds but sometimes increases transient reactive intermediates. In contrast, predicted lower activity (often described as “low”) may be associated with slower conversion of certain compounds, which can prolong presence of the parent molecule. These patterns are associations, not diagnoses. Interpretation is most meaningful alongside measured toxicant concentrations and other detox-related genetic markers on the full Toxin Zoomer panel, because overall clearance and biological impact depend on multiple pathways and exposures.

Featured Test

CYP1A2 (rs762551) is included in the Toxin Zoomer to evaluate phase I metabolic tendencies that shape how environmental chemicals are initially processed. Paired with urinary toxicant measurements and other detox genes, this marker helps clinicians see whether measured exposures reflect slower clearance, faster transformation, or variable activation—supporting more personalized interpretation of toxic burden.

View Toxin Zoomer

CYP1A2 (rs762551) FAQs

What is CYP1A2 (rs762551) and why is it important?

rs762551 is a single-letter genetic change in the CYP1A2 gene that is linked to differences in enzyme activity. That enzyme performs early chemical changes on many environmental compounds and some drugs. Knowing this variant helps explain why two people with similar exposures can have different measured toxicant patterns or sensitivity.

What does it mean if my CYP1A2 (rs762551) levels are low?

A low or reduced predicted CYP1A2 activity suggests slower phase I processing for substrates of this enzyme. That can be associated with longer presence of some parent compounds in the body and different patterns of metabolites. Clinical interpretation requires comparing this result with urinary toxicant levels and other genetic markers on the full panel.

What does it mean if my CYP1A2 (rs762551) levels are high?

Higher predicted CYP1A2 activity suggests faster initial conversion of certain chemicals and compounds. That may shorten exposure to some parent toxins but can sometimes increase temporary formation of reactive intermediates. These implications depend on the specific toxicants measured and other detoxification pathways, so context from the full report matters.

Why is this biomarker included in the Toxin Zoomer?

CYP1A2 rs762551 helps map an individual’s phase I metabolic tendency, which affects how environmental chemicals are transformed. When combined with measured toxicant loads and other detox genes, it improves interpretation of exposure patterns and supports more personalized clinical assessment.

Browse Articles

How Mycotoxins Trigger Mast Cell Activation and Brain Inflammation

Many patients with chronic, unexplained symptoms have a history of mold exposure that’s never been fully explored. What begins as vague fatigue or hea...

Brendan Vermeire

Aug 13, 2025

Neural Health Toxins

How Toxin Exposure Impacts Your Cardiometabolic Health

A common theme among many of my nutrition clients is that despite eating well, staying active, and managing stress, they feel worn down, inflamed, and...

Leslie Weidner, RDN

Aug 13, 2025

Cardiovascular Health Toxins Longevity

Heavy Metals: Exposure, Oxidative Stress, & Disease Development

Heavy metals are found naturally on Earth in soil, rocks, bodies of water, and in trace amounts inthe atmosphere. However, human activities have alter...

Jamie Haleva

Jul 2, 2025

Toxins Longevity

The Impact of Endocrine Disruptors on Menopause: Exposure, Testing, and Solutions

By some estimates, environmental factors may be the cause of 24% of human diseases and disorders around the world, according to the Endocrine Society....

Leslie Weidner, RDN

Apr 23, 2025

Hormones Toxins

About Vibrant:

The Experts Behind  Every Test

Our team is built on collaboration across disciplines to advance the science of wellness and longevity. At Vibrant Wellness, lab scientists, technologists, clinical researchers, doctors, practitioners, longevity advisors, engineers, and regulatory experts work side by side to transform diagnostics.

By uniting diverse expertise under one mission, we pioneer precision testing that empowers providers to uncover root causes, personalize care plans, and optimize patient health outcomes. Every test we develop reflects this commitment—to push boundaries in functional medicine, deliver clear, actionable insights, and support clinicians in helping patients live healthier, longer lives.

View All Tests

Results trusted by over 18,000 functional wellness professionals

We’re the leading provider of specialty wellness lab testing because we develop our testing with rigorous, ongoing research by top clinical experts, doctors, and scientists.

The gold standard of accuracy in  the lab industry

Our tests run on a proprietary 3Dense microchip technology platform that boasts unrivaled specificity and sensitivity. While most other labs carry only CLIA certification, we're CAP-accredited by the College of American Pathologists.

Our Clinical Support Team

We understand that patient care doesn't end with diagnosis. To achieve Vibrant health, patients need clinical support and
obtainable lifestyle changes. Our clinical support team helps providers make informed treatment recommendations, resulting in  better patient outcomes.

Mary Beth Augustine

DCN, RDN, FAND- Lead Clinical Educator

Suzanne Barker

MS, RDN, LD, CTTS, CGP- Clinical Educator

Suzette Garcia

MSc- MHNE- Clinical Educator

Brooke Mader Ganev

MS, CNS, LDN, FDN- Clinical Educator

Adair Anderson

MS, RDN, LDN- Clinical Educator

Lillie Luu Nguyen

DCN, CNS, LDN- Clinical Educator

Jason Barker

ND- Clinical Educator

Emaline Brown

ND- Clinical Educator

Dana Filatova

DCN, CNS, LDN- Clinical Educator

Jessy Dhanjal

ND- Clinical Educator

Nour Amri

MS, LDN, CNS, CKNS- Clinical Educator

Ready to Elevate Your Approach to Precision Wellness?

At Vibrant Wellness, we’re redefining the future of diagnostics—making complex science clear, accessible, and actionable. Whether you're a provider advancing personalized care or a patient seeking data-driven answers, our precision testing gives you the clarity to make informed decisions. Experience the next generation of functional medicine through clinically validated insights and seamless testing solutions.

Become a Provider

Become a Patient